全切髓术与根管治疗处理有不可逆性牙髓炎症状和体征牙齿的有效性比较:基于关联随机临床试验个体参与者数据的前瞻性Meta分析方案(PROVE)
该方案拟对10个国家正在开展的10项平行组随机试验(超过500名参与者)进行个体参与者数据前瞻性Meta分析,比较全切髓术与根管治疗在不可逆性牙髓炎牙齿中的临床和成本效果。主要结局为复合指标:无不可逆性牙髓炎疼痛、无急慢性根尖周炎症状体征、无影像学失败证据。将采用两阶段Meta分析合并效应量,并进行成本效果分析。
要点
- 全切髓术作为不可逆性牙髓炎替代根管治疗的证据有限,多来自把握度不足、偏倚风险高的研究。
- 该前瞻性Meta分析纳入10国10项随机试验的个体参与者数据,样本量超过500名参与者。
- 主要结局为复合指标:无不可逆性牙髓炎疼痛、无急慢性根尖周炎症状体征、无影像学失败证据。
核心结论
- 该前瞻性Meta分析旨在为全切髓术与根管治疗相比的临床和成本效果提供稳健证据,其结果将对临床实践实施和结构化临床指南制定产生影响。
研究设计与样本
- 前瞻性Meta分析,获取由多国研究者联盟设计并实施的系列随机试验的个体参与者数据;10个国家的10项平行组随机试验正在开展,将提供超过500名参与者的数据;各试验使用统一方案、定义结局和结局测量;个体参与者数据由两名独立评价者在Meta分析前获取、评估和质量核查;采用两阶段Meta分析方法,第一阶段在各试验内进行标准回归分析产生效应估计的聚合数据,随后进行逆方差加权Meta分析合并这些聚合数据并产生汇总统计量和森林图;基于复合结局进行成本效果分析作为过程评价,评估治疗保真度以及患者和牙医的接受度。
主要发现
- 研究问题和试验方案由所有10个研究点的主要研究者制定并批准。
- 所有研究点使用共享资源包括研究方案、数据收集表、参与者信息单和知情同意书,以提高流程、一致性和可重复性。
- 各研究点自行获得机构审查委员会批准,试验已在适当的开放获取平台注册。
- 截至2023年7月,大多数研究点已开始患者招募。
关键数值与推荐
- 主要结局为复合指标,定义为:(1)无提示不可逆性牙髓炎的疼痛;(2)无提示急性或慢性根尖周炎的体征和症状;(3)无影像学失败证据包括透射区或吸收。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Full pulpotomy has been proposed as an alternative to root canal treatment in teeth with signs and symptoms indicative of irreversible pulpitis (IRP), but the evidence is limited, relying on underpowered studies with a high risk of bias. The aim of this study is to conduct a prospective meta-analysis (PMA) of individual participant data of a series of individual randomised trials to provide robust evidence on the clinical and cost-effectiveness of pulpotomy compared with root canal treatment. METHODS: Individual participant data will be obtained from a series of randomised trials designed and conducted by a consortium of multi-national investigators with an interest in vital pulp treatment. These individualised trials will be conducted using a specified protocol, defined outcomes, and outcome measures. Ten parallel-group randomised trials currently being conducted in 10 countries will provide data from more than 500 participants. The primary outcome is a composite measure defined as (1) the absence of pain indicative of IRP, (2) the absence of signs and symptoms indicative of acute or chronic apical periodontitis, and (3) the absence of radiographic evidence of failure including radiolucency or resorption. Individual participant data will be obtained, assessed, and checked for quality by two independent reviewers prior to the PMA. Pooled estimates on treatment effects will be generated using a 2-stage meta-analysis approach. The first stage involves a standard regression analysis in each trial to produce aggregate data on treatment effect estimates followed by an inverse variance weighted meta-analysis to combine these aggregate data and produce summary statistics and forest plots. Cost-effectiveness analysis based on the composite outcome will be undertaken as a process evaluation to evaluate treatment fidelity and acceptability by patients and dentists. RESULTS: The research question and trial protocol were developed and approved by investigators in all 10 sites. All sites use shared resources including study protocols, data collection forms, participant information leaflets, and consent forms in order to improve flow, consistency, and reproducibility. Each site obtained its own Institutional Review Board approval, and trials were registered in appropriate open access platforms. Patient recruitment has started in most sites, as of July 2023. DISCUSSION: PMA offers a rigorous, flexible, and efficient methodology to answer this important research question and provide results with improved generalisability and external validity compared with traditional trials and retrospective meta-analyses. The results of this study will have implications for both the delivery of clinical practice and structured clinical guidelines' development. TRIAL REGISTRATION: PROSPERO CRD42023446809. Registered on 08 February 2023.
引用
- El Karim IA, Duncan HF, Fouad AF, et al. Effectiveness of full Pulpotomy compared with Root canal treatment in managing teeth with signs and symptOms indicative of irreversible pulpitis: a protocol for prospectiVE meta-analysis of individual participant data of linked randomised clinical trials (PROVE). Trials. 2023. PMID: 38102685. doi:10.1186/s13063-023-07836-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。